Long-term treatment with suberythropoietic epo is vaso- and neuroprotective in experimental diabetic retinopathy

Cellular Physiology and Biochemistry

Volumn 27, Issue 6, 2011, Pages 769-782

  Wang, Qian ^a   Gorbey, Stefan ^a   Pfister, Frederick ^a   Höger, Simone ^a   Dorn Beineke, Andrea ^a   Krügel, Katja ^b   Berrone, Elena ^c   Wu, Liang ^a   Korff, Thomas ^d   Lin, Jihong ^a   Busch, Stefanie ^a   Reichenbach, Andreas ^b   Feng, Yuxi ^a   Hammes, Hans Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Acellular capillaries; Diabetic retinopathy; Erythropoietin; Neurodegeneration; Pericyte loss

Indexed keywords

ERYTHROPOIETIN; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; LEUKOSTASIS; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTECTION; RETINA BLOOD VESSEL; THERAPY EFFECT; VASOPROTECTION;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 79959401477     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000330085     Document Type: Article

References (70)

1. Frank RN: Diabetic retinopathy. N Engl J Med 2004;350:48-58. (Pubitemid 38032183)
2. Lindahl P, Johansson BR, Leveen P, Betsholtz C: Pericyte loss and microaneurysm formation in PDGF-Bdeficient mice. Science 1997;277:242-245. (Pubitemid 27446080)
3. Hammes HP: Pericytes and the pathogenesis of diabetic retinopathy. Horm Metab Res 2005;37:39-43.
4. Hammes HP, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Brownlee M, Deutsch U: Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 2002;51:3107-3112.
5. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LEH: Suppression of Retinal Neovascularization in-Vivo by Inhibition of Vascular Endothelial Growth-Factor (Vegf) Using Soluble Vegf-Receptor Chimeric Proteins. Proc Natl Acad Sci USA 1995;92:10457-10461.
6. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA, Miller JW: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66-71. (Pubitemid 26026196)
7. Chibbery R, Ben-Mahmud BM, Chibber S, Kohner EM: Leukocytes in diabetic retinopathy. Curr Diabetes Rev 2007;3:3-14. (Pubitemid 46592789)
8. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP: A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-1452. (Pubitemid 39561611)
9. McLeod DS, Lefer DJ, Merges C, Lutty GA: Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol 1995;147:642-653.
10. Hammes HP, Federoff HJ, Brownlee M: Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med 1995;1:527-534.
11. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW: Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998;102:783-791. (Pubitemid 28399611)
12. Martin PM, Roon P, Van Ells TK, Ganapathy V, Smith SB: Death of retinal neurons in streptozotocin-induced diabetic mice. Invest Ophthalmol Vis Sci 2004;45:3330-3336. (Pubitemid 39121873)
13. Gastinger MJ; Singh RS, Barber AJ: Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci 2006;47:3143-50. (Pubitemid 351639794)
14. Barber AJ: A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:283-290. (Pubitemid 36351495)
15. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487. (Pubitemid 24356306)
16. Gerber HP, Dixit V, Ferrara N: Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998;273:13313-13316. (Pubitemid 28246905)
17. Nishijima KYS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT: Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53-67. (Pubitemid 47339226)
18. Sondell M, Lundborg G, Kanje M: Vascular endothelial growth factor stimulates Schwann cell invasion and neovascularization of acellular nerve grafts. Brain Res 1999;846:219-228. (Pubitemid 29505158)
19. Falk T, Zhang S, Sherman SJ: Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease. Mol Neurodegener 2009;4:49.
20. Spuch C, Antequera D, Portero A, Orive G, Hernandez RM, Molina JA, Bermejo-Pareja F, Pedraz JL, Carro E: The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer's disease. Biomaterials 2010;31:5608-5618.
21. Hochhauser E, Pappo O, Ribakovsky E, Ravid A, Kurtzwald E, Cheporko Y, Lelchuk S, Ben-Ari Z: Recombinant human erythropoietin attenuates hepatic injury induced by ischemia/reperfusion in an isolated mouse liver model. Apoptosis 2008;13:77-86.
22. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H: Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Eng J Med 2005;353:782-792. (Pubitemid 41215487)
23. Watanabe D: [Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy]. Nippon Ganka Gakkai Zasshi 2007;111:892-898.
24. Wakida K, Shimazawa M, Hozumi I, Satoh M, Nagase H, Inuzuka T, Hara H: Neuroprotective effect of erythropoietin, and role of metallothionein-1 and -2, in permanent focal cerebral ischemia. Neuroscience 2007;148:105-114. (Pubitemid 47211609)
25. Wang Q, Pfister F, Dorn-Beineke A, Vom Hagen F, Lin J, Feng Y, Hammes HP: Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina. Diabetologia 2010;53:1227-1238.
26. Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ, van Gilst WH, Schoemaker RG: Timing of erythropoietin treatment for cardioprotection in ischemia/ reperfusion. J Cardiovasc Pharmacol 2004;44:473-479. (Pubitemid 39305089)
27. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM: Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004;15:2115-2124. (Pubitemid 39031350)
28. Wu H, Ren B, Zhu J, Dong G, Xu B, Wang C, Zheng X, Jing H: Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats. Eur J Cardiothorac Surg 2006;29:902-907. (Pubitemid 43728600)
29. Guneli E, Cavdar Z, Islekel H, Sarioglu S, Erbayraktar S, Kiray M, Sokmen S, Yilmaz O, Gokmen N: Erythropoietin protects the intestine against ischemia/ reperfusion injury in rats. Mol Med 2007;13:509-517. (Pubitemid 47585745)
30. Nowicki M: Erythropoietin and hypertension. J Hum Hypertens 1995;9:81-88.
31. Lemmer B, Mattes A, Bohm M, Ganten D: Circadian blood pressure variation in transgenic hypertensive rats. Hypertension 1993;22:97-101. (Pubitemid 23187390)
32. Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G: Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998;47:401-406. (Pubitemid 28104202)
33. Berrone E, Beltramo E, Buttiglieri S, Tarallo S, Rosso A, Hammes HP, Porta M: Establishment and characterization of a human retinal pericyte line: a novel tool for the study of diabetic retinopathy. Int J Mol Med 2009;23:373-378.
34. Grundt A, Grundt C, Gorbey S, Thomas MA, Lemmer B: Strain-dependent differences of restraint stress-induced hypertension in WKY and SHR. Physiol Beha, 2009;97:341-346.
35. Steinle JJ, Kern TS, Thomas SA, McFadyen-Ketchum LS, Smith CP: Increased basement membrane thickness, pericyte ghosts, and loss of retinal thickness and cells in dopamine beta hydroxylase knockout mice. Exp Eye Res 2009;88:1014-1019.
36. Swift S, Ellison AR, Kassner P, McCaffery I, Rossi J, Sinclair AM, Begley CG, Elliott S: Absence of functional EpoR expression in human tumor cell lines. Blood 2010;115:4254-4263.
37. Rabie T, Marti HH: Brain protection by erythropoietin: a manifold task. Physiology (Bethesda) 2008;23:263-274.
38. Bernaudin M, Bellail A, Marti HH, Yvon A, Vivien D, Duchatelle I, Mackenzie ET, Petit E: Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 2000;30:271-278. (Pubitemid 30259666)
39. Weishaupt JH, Rohde G, Polking E, Siren AL, Ehrenreich H, Bahr M: Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest Ophthalmol Vis Sci 2004;45:1514-1522. (Pubitemid 38859333)
40. Eschbach JW, Adamson JW: Erythropoietin: issues in its use as a therapeutic for the anemia of chronic renal failure. Blood Purif 1990;8:239-254.
41. Muntzel M, Hannedouche T, Lacour B, Drueke TB: Erythropoietin increases blood pressure in normotensive and hypertensive rats. Nephron 1993;65:601-604. (Pubitemid 23341514)
42. Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, Musashi K, Yoshimura N: Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005;46:1440-1444. (Pubitemid 41685887)
43. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2000;9:669-676. (Pubitemid 36749215)
44. Genc S, Koroglu TF, Genc K: Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 2004;22:105-119. (Pubitemid 38850338)
45. Mizutani M, Kern TS, Lorenzi M: Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996;97:2883-2890. (Pubitemid 26197103)
46. Hammes HP, Feng Y, Pfister F, Brownlee M: Diabetic retinopathy: targeting vasoregression. Diabetes 2011,60:9-16.
47. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-10531.
48. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT: Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994;91:3974-3978. (Pubitemid 24139555)
49. Digicaylioglu M, Lipton SA: Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001;412:641-647. (Pubitemid 32772276)
50. Bogoyevitch MA: An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 2004;63:208-216. (Pubitemid 38900835)
51. Marzo F, Lavorgna A, Coluzzi G, Santucci E, Tarantino F, Rio T, Conti E, Autore C, Agati L, Andreotti F: Erythropoietin in heart and vessels: focus on transcription and signalling pathways. J Thromb Thrombolysis 2008;26:183-187.
52. Zheng L, Szabo C, Kern TS: Poly(ADPribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 2004;53:2960-2967. (Pubitemid 39425922)
53. Eichler W, Kuhrt H, Hoffmann S, Wiedemann P, Reichenbach A: VEGF release by retinal glia depends on both oxygen and glucose supply. Neuroreport 2000;11:3533-3537.
54. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE: Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995;92:905-909.
55. Krugel K, Wurm A, Linnertz R, Pannicke T, Wiedemann P, Reichenbach A, Bringmann A: Erythropoietin inhibits osmotic swelling of retinal glial cells by Janus kinase-and extracellular signalregulated kinases1/2-mediated release of vascular endothelial growth factor. Neuroscience 2009;165:1147-1158.
56. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP: Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001;158:147-152. (Pubitemid 32096479)
57. Gubitosi-Klug RA, Talahalli R, Du Y, Nadler JL, Kern TS: 5-Lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy. Diabetes 2008;57:1387-1393.
58. Sims B, Clarke M, Njah W, Hopkins ES, Sontheimer H: Erythropoietin- induced neuroprotection requires cystine glutamate exchanger activity. Brain Res 2010;1321:88-95.
59. Grasso G, Graziano F, Sfacteria A, Carletti F, Meli F, Maugeri R, Passalacqua M, Certo F, Fazio M, Buemi M, Iacopino DG: Neuroprotective effect of erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage. Neurosurgery 2009;65:763-769.
60. Baumgartner WA: Etiology, pathogenesis, and experimental treatment of retinitis pigmentosa. Med Hypotheses 2000;54:814-824. (Pubitemid 30327673)
61. Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N, Lauria G, Borgna M, Lombardi R, Cimen B, Comelekoglu U, Kanik A, Tataroglu C, Cerami A, Ghezzi P: Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA 2004;101:823-828. (Pubitemid 38121042)
62. Zhang J, Wu Y, Jin Y, Ji F, Sinclair SH, Luo Y, Xu G, Lu L, Dai W, Yanoff M, Li W, Xu GT: Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci 2008;49:732-742.
63. Wang HY, Niu YJ, Wang PS, Zhou ZY, Liu FL, Yang WY, Zhang YH: [Erythropoietin administration protects retina against light-induced retinal degeneration]. Zhonghua Yan Ke Za Zhi 2005;41:434-438.
64. Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, Samardzija M, Bauer C, Gassmann M, Reme CE: HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 2002;8:718-724. (Pubitemid 34778725)
65. Kern TS, Barber AJ: Retinal ganglion cells in diabetes. J Physiol 2008;586:4401-4408.
66. Sola A, Wen TC, Hamrick SE, Ferriero DM: Potential for protection and repair following injury to the developing brain: a role for erythropoietin? Pediatr Res 2005;57:110R-117R. (Pubitemid 40593255)
67. Kawakami M, Iwasaki S, Sato K, Takahashi M: Erythropoietin inhibits calcium-induced neurotransmitter release from clonal neuronal cells. Biochem Biophys Res Commun 2000;279:293-297.
68. Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M: Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 2001;276:39469-39475.
69. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, Wyns S, Thijs V, Andersson J, van Marion I, Al-Chalabi A, Bornes S, Musson R, Hansen V, Beckman L, Adolfsson R, Pall HS, Prats H, Vermeire S, Rutgeerts P, Katayama S, Awata T, Leigh N, Lang-Lazdunski L, Dewerchin M, Shaw C, Moons L, Vlietinck R, Morrison KE, Robberecht W, Van Broeckhoven, C, Collen D, Andersen PM, Carmeliet P: VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-394. (Pubitemid 36935331)
70. Brines, M, Cerami A: Erythropoietinmediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008;264:405-432.